Must listen podcast episode from Roger Green, who delivers more epiphanic moments in Liver Disease coverage than Nikola Jokić has triple doubles.
Latest Episode
S6.4 – Reasons for Optimism in MASLD Drug Development and Patient Advocacy
SurfingMASH concludes its coverage of the Emerging Trends Conference looking at an encouraging future in MASLD drug development and increasing interest in patient advocacy.
SUMMARY
“This week’s expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class.
First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics’s efruxifermin, 89bio’s pegozafermin, and Boston Pharmaceuticals’s efimosfermin. He points to efruxifermin’s 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug’s duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin’s publication of data in the New England Journal of Medicine and efimosfermin’s promising data based on monthly dosing.
Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials.
Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies.”
